Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors

Samantha Perino(Enveda Therapeutics (United States)), Kerry A. Whalen(Enveda Therapeutics (United States))

Molecular Cancer Therapeutics

June 4, 2020

10.1158/1535-7163.mct-19-0964

Cited by 11

Related Papers

Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

|Cancer Research|2022|11